drugset

drugset / Trial / NCT03819660

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

NCT03819660 ↗

Phase 2 Terminated 13 enrolled Catalyst Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A long term safety study of amifampridine phosphate in patients with spinal muscular atrophy (SMA) Type 3.

Timeline

Start: 2019-03-07
Primary completion: 2021-09-13
Completion: 2021-09-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amifampridine	Small molecule	10 mg	Oral

Indications